Zolpidem in Parkinson's disease.
Daniele
A
A
Albanese
A
A
Gainotti
G
G
Gregori
B
B
Bartolomeo
P
P
D000978:Antiparkinson Agents / Q000627:therapeutic use*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D005917:Globus Pallidus / Q000187:drug effects; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D008875:Middle Aged; D009048:Motor Skills / Q000187:drug effects / Q000502:physiology; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D010919:Placebos; D011725:Pyridines / Q000627:therapeutic use*; D018079:Receptors, GABA / Q000187:drug effects; D013378:Substantia Nigra / Q000187:drug effects; D000077334:Zolpidem
D000978:Antiparkinson Agents; D006993:Hypnotics and Sedatives; D010919:Placebos; D011725:Pyridines; D018079:Receptors, GABA; D000077334:Zolpidem